These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 27067842)

  • 1. [Molecular Subtypes of Gastric Cancer].
    Hatogai K; Doi T
    Gan To Kagaku Ryoho; 2016 Mar; 43(3):281-5. PubMed ID: 27067842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemistry as a surrogate for molecular subtyping of gastric adenocarcinoma.
    Gonzalez RS; Messing S; Tu X; McMahon LA; Whitney-Miller CL
    Hum Pathol; 2016 Oct; 56():16-21. PubMed ID: 27342907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 testing in gastric cancer.
    Albarello L; Pecciarini L; Doglioni C
    Adv Anat Pathol; 2011 Jan; 18(1):53-9. PubMed ID: 21169738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging molecular classifications and therapeutic implications for gastric cancer.
    Chen T; Xu XY; Zhou PH
    Chin J Cancer; 2016 May; 35():49. PubMed ID: 27233623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive molecular characterization of gastric adenocarcinoma.
    Cancer Genome Atlas Research Network
    Nature; 2014 Sep; 513(7517):202-9. PubMed ID: 25079317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer.
    Bang YJ
    J Clin Gastroenterol; 2012 Sep; 46(8):637-48. PubMed ID: 22751336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of HER2 expression with clinicopathological characteristics and prognosis in resectable gastric cancer.
    Otsu H; Oki E; Ikawa-Yoshida A; Kawano H; Ando K; Ida S; Kimura Y; Aishima S; Saeki H; Morita M; Kohnoe S; Oda Y; Maehara Y
    Anticancer Res; 2015 Apr; 35(4):2441-6. PubMed ID: 25862912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 testing in gastric and esophageal adenocarcinoma: new diagnostic challenges arising from new therapeutic options.
    Koltz BR; Hicks DG; Whitney-Miller CL
    Biotech Histochem; 2012 Jan; 87(1):40-5. PubMed ID: 21745161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?
    Lorenzen S; Lordick F
    Curr Opin Oncol; 2011 Jul; 23(4):396-402. PubMed ID: 21505336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relation of HER2 status and prognosis in gastric cancer patients].
    Fuse N
    Gan To Kagaku Ryoho; 2011 Jul; 38(7):1073-8. PubMed ID: 21772089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.
    Yano T; Doi T; Ohtsu A; Boku N; Hashizume K; Nakanishi M; Ochiai A
    Oncol Rep; 2006 Jan; 15(1):65-71. PubMed ID: 16328035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer.
    Lordick F
    Future Oncol; 2011 Feb; 7(2):187-99. PubMed ID: 21345138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular classification of gastric cancer.
    Röcken C
    Expert Rev Mol Diagn; 2017 Mar; 17(3):293-301. PubMed ID: 28118758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic and epigenomic heterogeneity in molecular subtypes of gastric cancer.
    Lim B; Kim JH; Kim M; Kim SY
    World J Gastroenterol; 2016 Jan; 22(3):1190-201. PubMed ID: 26811657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
    Hechtman JF; Polydorides AD
    Arch Pathol Lab Med; 2012 Jun; 136(6):691-7. PubMed ID: 22646280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular classification of gastric adenocarcinoma: translating new insights from the cancer genome atlas research network.
    Sunakawa Y; Lenz HJ
    Curr Treat Options Oncol; 2015 Apr; 16(4):17. PubMed ID: 25813036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted HER2 treatment in advanced gastric cancer.
    Jørgensen JT
    Oncology; 2010; 78(1):26-33. PubMed ID: 20185938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Predictive diagnosis of HER2 in gastric adenocarcinoma].
    Daum O; Skálová A; Rozkos T; Laco J
    Cesk Patol; 2011 Oct; 47(4):160-3. PubMed ID: 22145214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced HER2-positive gastric cancer: current and future targeted therapies.
    Pazo Cid RA; Antón A
    Crit Rev Oncol Hematol; 2013 Mar; 85(3):350-62. PubMed ID: 23021388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond.
    Gomez-Martín C; Lopez-Rios F; Aparicio J; Barriuso J; García-Carbonero R; Pazo R; Rivera F; Salgado M; Salud A; Vázquez-Sequeiros E; Lordick F
    Cancer Lett; 2014 Aug; 351(1):30-40. PubMed ID: 24943493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.